Publications
47
Citations
442
Est. group size
—
Recurring co-author estimate
Active years
17
Publishing since 2009
Hsing-Hui Wang's research focuses on how the immune system responds to cancer treatments, particularly in head and neck cancer and bladder cancer. Work includes studying combined radiation and immune-based therapies for patients with head and neck cancer who cannot tolerate standard chemotherapy, and analyzing immune cell and antigen features that predict how bladder cancer patients respond to combined chemotherapy and immunotherapy before surgery. Related work also examines immune cell behavior in autoimmune diabetes.
Publication output was low and steady for years before a large spike in 2023 (driven largely by a single study and its associated supplementary materials), followed by a return to a low, modest level in 2024–2025.
Generated by claude-sonnet-5 from public bibliographic data · Jul 20, 2026
- Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
UNC Libraries · 2025
- UTX coordinates TCF1 and STAT3 to control progenitor CD8+ T cell fate in autoimmune diabetes
Journal of Clinical Investigation · 2025
- Immune features are associated with response to neoadjuvant chemo-immunotherapy for muscle-invasive bladder cancer
Nature Communications · 2024
- Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary figure 3: Cytokines and Chemokines from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary figure 4: PFS and OS by ajcc8 from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Data from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Figure 1: B cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Supplementary Figure 2: T cell gating from Concurrent Definitive Immunoradiotherapy for Patients with Stage III–IV Head and Neck Cancer and Cisplatin Contraindication
2023
- Journal of Clinical and Translational Science×2
- Nature Communications×1
- Clinical Cancer Research×1
- JCI Insight×1
- Communications Biology×1
- Masanari Kato
Medicine · The Ohio State University
- Abberly Lott Limbach
Medicine · The Ohio State University
- Enver Özer
Medicine · The Ohio State University
- Amit Agrawal
Medicine · The Ohio State University
- E. Ozer
Medicine · The Ohio State University
This profile was generated automatically from public scholarly data (OpenAlex). Group size and activity levels are estimates derived from co-authorship patterns.
Last updated Jul 20, 2026.
Claim or correct this profile